retatrutide clinical trials philippines ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial The outlook for obesity from
Description
Buczyska et al., 2021
Retatrutide: A newer triple-agonist compound still in clinical trials
Here is what happened when I tried both
Weight loss plateaus are a normal part of the process reflecting metabolic adaptation, not medication failure
Treatment with semaglutide 2.4 mg also significantly improved symptoms, evaluated with the Kansas City Cardiomiopathy Questionnaire, and physical limitations, evaluated with the 6 min walking test, in the STEP-HFpEF trial, enrolling 529 patients with obesity and HF with preserved ejection fraction 89
But until now, they have largely been available in the U.S
